Novartis AG has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, related to its tender offer to acquire all outstanding shares of Regulus Therapeutics Inc. The expiration of this waiting period, which occurred at 11:59 p.m. on June 20, 2025, is a crucial step towards the completion of the transaction. Under the agreement, Novartis will offer $7.00 in cash per share of Regulus, along with a contingent value right for a potential additional payment of $7.00 in cash, contingent on the achievement of a regulatory milestone. The tender offer is set to expire one minute past 11:59 p.m. on June 24, 2025, unless extended or terminated earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。